WHO cautions against coronavirus 'immunity passports'

By The Science Advisory Board staff writers

April 27, 2020 -- The World Health Organization (WHO) has published a report expressing caution about the value of antibody tests for the novel coronavirus and saying that evidence for immunity after exposure is lacking.

The organization expressed its views on antibody testing in a scientific brief published on April 24. It noted that some governments are looking to use antibody tests to prove immunity, so-called "immunity passports," enabling citizens to return to work and for economies to reopen. However, there is no evidence that people who have recovered from COVID-19 and have antibodies are protected from getting infected a second time, the WHO stated. Studies indicate that people do have antibodies after recovering from infection, but some "have very low levels of neutralizing antibodies in their blood, suggesting that cellular immunity may also be critical for recovery."

"As of 24 April 2020, no study has evaluated whether the presence of antibodies to SARS-CoV-2 confers immunity to subsequent infection by this virus in humans," the WHO wrote.

The WHO also flagged risks associated with inaccurate antibody tests, including false negatives and false positives, both of which have serious consequences, and raised questions about whether the tests can discriminate between antibodies to different kinds of coronaviruses. On Twitter, the organization clarified that it expects most people who are infected with COVID-19 will develop an antibody response that provides some level of protection, but the level and length of time of that protection is unknown.

As of April 26, more than 2.9 million cases had been confirmed worldwide, with more than 190,000 deaths, according to the WHO's latest situation report on the novel coronavirus.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.